BE731578A - - Google Patents
Info
- Publication number
- BE731578A BE731578A BE731578DA BE731578A BE 731578 A BE731578 A BE 731578A BE 731578D A BE731578D A BE 731578DA BE 731578 A BE731578 A BE 731578A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- calcium
- fluorine
- water
- mixture
- Prior art date
Links
- 239000011737 fluorine Substances 0.000 claims description 39
- 229910052731 fluorine Inorganic materials 0.000 claims description 39
- 229910001868 water Inorganic materials 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 159000000007 calcium salts Chemical class 0.000 claims description 7
- 229940074371 monofluorophosphate Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 229940126601 medicinal product Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 2
- 235000019156 vitamin B Nutrition 0.000 claims 2
- 239000011720 vitamin B Substances 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 38
- 239000011575 calcium Substances 0.000 description 32
- 241000700159 Rattus Species 0.000 description 21
- 229910052791 calcium Inorganic materials 0.000 description 19
- 229920002472 Starch Polymers 0.000 description 18
- 229960005069 calcium Drugs 0.000 description 18
- 229940091249 fluoride supplement Drugs 0.000 description 18
- 239000008107 starch Substances 0.000 description 18
- 235000019698 starch Nutrition 0.000 description 18
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 12
- 229910004877 Na2PO3F Inorganic materials 0.000 description 11
- 229910018819 PO3F Inorganic materials 0.000 description 11
- 239000001354 calcium citrate Substances 0.000 description 10
- 239000004227 calcium gluconate Substances 0.000 description 10
- 235000013927 calcium gluconate Nutrition 0.000 description 10
- 229960004494 calcium gluconate Drugs 0.000 description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 description 10
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 235000013337 tricalcium citrate Nutrition 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- 230000033558 biomineral tissue development Effects 0.000 description 9
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 9
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- -1 iron ions Chemical class 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000011775 sodium fluoride Substances 0.000 description 6
- 235000013024 sodium fluoride Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940050410 gluconate Drugs 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000005115 demineralization Methods 0.000 description 3
- 230000002328 demineralizing effect Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical class [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 2
- 229910001634 calcium fluoride Inorganic materials 0.000 description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000002222 fluorine compounds Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 229910004697 CaPO3F Inorganic materials 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100003996 Mus musculus Atrn gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000013860 dentinogenesis Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE731578 | 1969-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE731578A true BE731578A (enrdf_load_stackoverflow) | 1969-10-01 |
Family
ID=3854608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE731578D BE731578A (enrdf_load_stackoverflow) | 1969-04-16 | 1969-04-16 |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE731578A (enrdf_load_stackoverflow) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2170018A1 (enrdf_load_stackoverflow) * | 1972-02-02 | 1973-09-14 | Blendax Werke Schneider Co | |
| FR2202697A1 (enrdf_load_stackoverflow) * | 1972-10-13 | 1974-05-10 | Procter & Gamble | |
| FR2567757A1 (fr) * | 1984-07-19 | 1986-01-24 | Ganem Herve | Solution assurant, par injection de type mesotherapique, la consolidation des dents |
| FR2588189A1 (fr) * | 1985-10-03 | 1987-04-10 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| FR2604360A1 (fr) * | 1986-09-25 | 1988-04-01 | Colgate Palmolive Co | Medicament a liberation controlee pour fournir des ions fluorure |
| FR2604359A1 (fr) * | 1986-09-25 | 1988-04-01 | Colgate Palmolive Co | Medicament a liberation controlee pour fournir des ions fluorure |
| US5153005A (en) * | 1990-12-11 | 1992-10-06 | Colgate-Palmolive Company | Composition and method for preventing fluorosis |
| WO1994000101A1 (de) * | 1992-06-30 | 1994-01-06 | Wolfgang Wiedemann | Präparat zur prophylaktischen und therapeutischen behandlung von karies |
-
1969
- 1969-04-16 BE BE731578D patent/BE731578A/fr not_active IP Right Cessation
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2170018A1 (enrdf_load_stackoverflow) * | 1972-02-02 | 1973-09-14 | Blendax Werke Schneider Co | |
| FR2202697A1 (enrdf_load_stackoverflow) * | 1972-10-13 | 1974-05-10 | Procter & Gamble | |
| FR2567757A1 (fr) * | 1984-07-19 | 1986-01-24 | Ganem Herve | Solution assurant, par injection de type mesotherapique, la consolidation des dents |
| FR2588189A1 (fr) * | 1985-10-03 | 1987-04-10 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0227494A1 (en) * | 1985-10-03 | 1987-07-01 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Pharmaceutical composition of the type which undergoes liquid-gel phase transition |
| FR2604360A1 (fr) * | 1986-09-25 | 1988-04-01 | Colgate Palmolive Co | Medicament a liberation controlee pour fournir des ions fluorure |
| FR2604359A1 (fr) * | 1986-09-25 | 1988-04-01 | Colgate Palmolive Co | Medicament a liberation controlee pour fournir des ions fluorure |
| NL8702298A (nl) * | 1986-09-25 | 1988-04-18 | Colgate Palmolive Co | Medicament voor het verschaffen van fluoride-ionen voor de behandeling en preventie van met botverlies gepaard gaande ziekten. |
| NL8702297A (nl) * | 1986-09-25 | 1988-04-18 | Colgate Palmolive Co | Medicament voor het verschaffen van fluoride-ionen voor de behandeling en preventie van met botverlies gepaardgaande ziekten. |
| BE1000159A5 (fr) * | 1986-09-25 | 1988-06-28 | Colgate Palmolive Co | Medicament a liberation controlee pour fournir des ions fluorure. |
| BE1001657A5 (fr) * | 1986-09-25 | 1990-01-23 | Colgate Palmolive Co | Medicament a liberation controlee pour fournir des ions fluorure. |
| US5153005A (en) * | 1990-12-11 | 1992-10-06 | Colgate-Palmolive Company | Composition and method for preventing fluorosis |
| WO1994000101A1 (de) * | 1992-06-30 | 1994-01-06 | Wolfgang Wiedemann | Präparat zur prophylaktischen und therapeutischen behandlung von karies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1330307C (fr) | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol | |
| CH651208A5 (fr) | Composition pharmaceutique aqueuse diluee stabilisee pour l'administration du 1alpha,25-dihydroxycholecalciferol a des nouveaux-nes. | |
| JP2005504109A5 (enrdf_load_stackoverflow) | ||
| FR2604359A1 (fr) | Medicament a liberation controlee pour fournir des ions fluorure | |
| TWI330531B (en) | A composition for preparing carbon dioxide external gel and the carbon dioxide external gel | |
| BE731578A (enrdf_load_stackoverflow) | ||
| JP2018150359A (ja) | シトレートに富むカルシウム・マグネシウム補助剤およびその使用 | |
| CA2150417A1 (en) | Composition and method for the treatment of premenstrual syndrome | |
| US2721161A (en) | Ascorbic acid preparation | |
| JP2594576B2 (ja) | 持続性放出フッ化物組成物 | |
| JPH04225921A (ja) | 骨粗しょう症及びホルモン不均衡の治療用組成物 | |
| JP6288652B2 (ja) | アモルファスリン酸カルシウムを有する局所用口腔ユビキノールサプリメント組成物 | |
| JPS63503305A (ja) | 徐放性フッ化ナトリウム錠、その製法、およびオステオポローシスの治療方法 | |
| CA2909750C (fr) | Composition pharmaceutique, dietetique ou alimentaire liquide ou semi-liquide depourvue d'amertume contenant un sel d'arginine | |
| JP3503880B2 (ja) | 口腔用組成物 | |
| US9974804B1 (en) | Strontium-based composition, product, and method of using the same to control progression of osteoarthritis osteoporosis and tooth decay | |
| JPS6072817A (ja) | 鉄、亜鉛及びマグネシウムの代替物としての鉄（２価）塩、亜鉛塩、マグネシウム塩及びこれらの混合塩の改良 | |
| CN108125805A (zh) | 一种抗牙齿敏感的组合物及其口腔护理剂和制备方法 | |
| JP2757188B2 (ja) | かゆみ止め剤 | |
| RU2380081C2 (ru) | Состав для лечения и профилактики заболеваний полости рта | |
| KR0130427B1 (ko) | 복합 제산제 조성물 | |
| EP0865289B1 (fr) | Compositions a base d'arctium majus | |
| EP3678498A1 (en) | Composition for calcium supplementation | |
| JPS58152820A (ja) | 癌治療用組成物 | |
| EP1107766A2 (fr) | Utilisation du gluconate de lithium dans la fabrication d'un medicament pour le traitement de l'herpes et de la dermite seborrheique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: ERICSSON STEN INGVE Effective date: 19870430 |